Financial Times (Free subscription) | yesterday
Chris Viehbacher will soon celebrate a year in charge of Sanofi-Aventis, the French drugmaker. He became chief executive after the ousting of Gérard Le Fur, a...
thepharmaletter.com (Free subscription) | yesterday
Sanofi-Aventis chief executive Chris Viehbacher, in an interview with the UK’s Financial Times, again rejects the idea of large acquisitions. He also reiterates his policy of R&D externalization, acknowledging that the company historically had “not a lot of external partnerships, virtually no contact with our commercial organizations.”
Medical News Today (Free subscription) | 22/11/2009
Sanofi-aventis ( EURONEXT: SAN and NYSE: SNY) and Medicines for Malaria Venture (MMV) announced that they have entered an agreement to launch the largest safety and efficacy study of an antimalarial drug. This field-monitoring program on ASAQ, a fixed-dose combination of artesunate and amodiaquine, started in Côte d'Ivoire in October 2009. MMV is a not-for-profit drug research and development...
Jim Cramer's Mad Money (Free subscription) | yesterday
Jim Cramer’s Mad Money Stock Picks for Friday November 20 2009. These are all of Jim Cramer’s stock picks that are a Buy! I bold my picks. Buy: Sanofi-Aventis (SNY) Wynn Resorts (WYNN) ADC Telecommunications (ADCT) Lear Corp (LEA) Enterprise Products Partners (EPD) Kinder Morgan (KMP) Hewlett-Packard (HPQ) J Crew (JCG) Deere & Co (DE) HJ Heinz (HNZ) Frontline (FRO) Wellpoint (WLP) Sell:...
BloggingStocks (Free subscription) | yesterday
Filed under: Analyst reports , Pfizer (PFE) , Market matters , Bristol-Myers Squibb (BMY) , Merck and Co (MRK) , Lilly (Eli) (LLY) , Deere and Co (DE) , Stocks to Buy , Potash Corp. of Saskatchewan (POT) From TheStreet.com Network Dollar Store: Early Volume Plays Dollar Could Steer Stocks in Coming Week TheStreet.com's Jim Cramer says it looks like the patent worries aren't so dire after all. Now...
Financial Times (Free subscription) | 22/11/2009
The chief executive of Sanofi-Aventis criticises the past dominance of science over commerce in the French pharmaceuticals group and the stifling of the companies it acquired, as he lays out a distinctive strategy almost one year into the job
The IN VIVO Blog (Free subscription) | 20/11/2009
People, we seriously need to talk about Eggo Waffles. But first, a dearth of meaty deals this week has us thinking more about Bristol-Myers Squibb's share-swap/buyback/spin-off of its nutritionals unit Mead Johnson. We tried to make the point earlier this week that Bristol's move was too focused on short-term gain. Others have pointed out to us that without some sort of short-term gain to appease...
Seattle Times (Free subscription) | 20/11/2009
Idaho's Medicaid Division is getting nearly $115,000 as its share from a nationwide settlement with French drug giant Sanofi-Aventis.
Contract Pharma Breaking News (Free subscription) | 20/11/2009
Samir Ghodbane, Ph.D. , has been appointed as the new general manager of CMC services and CTM manufacturing at Frontage . Dr. Ghodbane has extensive experience and expertise in product development and technical operations spanning the complete product development cycle, as well as a comprehensive understanding of branded and generic pharmaceutical environments. He has led drug development and technical...
JJS Diabetes (Free subscription) | 20/11/2009
That doesn't include me .... but, if you're diabetic and use an iPhone, Sanofi-Aventis presents a a new application that helps you calculate the nutritional content of a meal. "GoMeals™” is a food tracking tool that allows you to search more than 25,000 foods and more than 200 restaurant menus to see breakdowns of carbohydrate, fat and protein content presented in a pie-chart fashion....
Medical News Today (Free subscription) | 20/11/2009
Pfizer and the Drugs for Neglected Diseases Initiative (DNDi) on Wednesday announced plans to team up in an effort to identify new drug candidates for the treatment of three tropical diseases, the Associated Press/Business Week reports. The scientists will test the efficacy of Pfizer drug candidates against sleeping sickness, visceral leishmaniasis, and Chagas disease.
Fiercebiotech (Free subscription) | 19/11/2009
The FDA's Vaccines and Related Biological Products Advisory Committee today will determine whether Protein Sciences' flu vaccine FluBlok, which can be produced in less than two months by inserting flu genes into an insect virus and growing it in caterpillar ovary cells, warrants approval. FluBlok can be produced in a third of the time it takes larger drugmakers, including Sanofi-Aventis, GlaxoSmithKline...
PR News Wire (Free subscription) | 19/11/2009
BRIDGEWATER, N.J., Nov. 19 /PRNewswire-FirstCall/ -- Sanofi-aventis U.S. announced today that GoMeals(TM), a new iPhone application (app) designed to help people living with diabetes make healthy food choices, is now available for download at the iTunes App store. GoMeals(TM) is a food tracking tool which allows users to search thousands of foods and dishes from popular restaurants and grocery stores...
The Economist (Free subscription) | 19/11/2009
Toyota spent the most on research and development (R&D) of any company in the world in 2008, according to the European Commission’s latest tally. The Japanese carmaker increased its annual R&D spending by 7.6% to €7.6 billion ($10.6 billion), knocking Microsoft off the top spot. Three of the five biggest spenders are carmakers, but pharmaceutical and biotechnology companies also...
The IN VIVO Blog (Free subscription) | 19/11/2009
The Food & Drug Administration's public health alert on Plavix is, as we point out in "The Pink Sheet" DAILY , a nice boost for Eli Lilly and Daiichi Sankyo, who market the competing platelet agent Effient . But the back story to this regulatory action merits closer attention by all pharmaceutical sponsors. This is no ordinary labeling change, and the implications of how the regulatory...
Videos